Compare PW & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PW | JAGX |
|---|---|---|
| Founded | 1967 | 2013 |
| Country | United States | United States |
| Employees | 2 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1M | 2.2M |
| IPO Year | N/A | 2014 |
| Metric | PW | JAGX |
|---|---|---|
| Price | $9.20 | $1.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $60.00 |
| AVG Volume (30 Days) | 6.5K | ★ 56.3K |
| Earning Date | 05-13-2026 | 04-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 82.42 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $11,511,000.00 |
| Revenue This Year | N/A | $61.58 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.50 | $0.22 |
| 52 Week High | $12.92 | $8.00 |
| Indicator | PW | JAGX |
|---|---|---|
| Relative Strength Index (RSI) | 56.37 | 24.67 |
| Support Level | $8.85 | $0.96 |
| Resistance Level | $11.62 | $1.98 |
| Average True Range (ATR) | 0.58 | 0.24 |
| MACD | -0.30 | -0.15 |
| Stochastic Oscillator | 20.83 | 13.00 |
Power REIT is an internally-managed real estate investment trust that owns a portfolio of real estate assets related to transportation, energy infrastructure and Controlled Environment Agriculture in the United States. Its assets consisted of approximately 112 miles of railroad infrastructure and related real estate which is owned by its subsidiary, approximately 447 acres of fee simple land leased to a utility scale solar power generating project with an aggregate generating capacity of approximately 82 Megawatts and approximately 82 acres of land with approximately 357,000 square feet of CEA properties in the form of greenhouses. The company invested in greenhouses for state-licensed cannabis and food cultivation.
Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.